Amgen's earnings call highlighted strong performance, driven by volume growth in newer products like Prolia and Repatha.  Management expressed optimism about the future, including the upcoming FDA review of Repatha's cardiovascular outcomes data and successful launch of biosimilars.  The company also addressed the substantial impact of Hurricane Maria on Puerto Rico facilities, outlining the recovery efforts' financial impact for the short and long term.  This suggests a positive outlook for Amgen, with continued strong performance projected for the near future.
[1]
